Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

dc.contributor.author	Häring, Hans-Ulrich
dc.date.accessioned	2014-09-18T11:00:15Z
dc.date.available	2014-09-18T11:00:15Z
dc.date.issued	2014
dc.identifier.issn	0149-5992
dc.identifier.uri	http://hdl.handle.net/10900/56282
dc.language.iso	en	de_DE
dc.publisher	Amer Diabetes Assoc	de_DE
dc.relation.uri	http://dx.doi.org/10.2337/dc13-2105	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20140813180100_00319	de_DE
utue.publikation.seiten	1650-1659	de_DE
utue.personen.roh	Haering, Hans-Ulrich
utue.personen.roh	Merker, Ludwig
utue.personen.roh	Seewaldt-Becker, Elke
utue.personen.roh	Weimer, Marc
utue.personen.roh	Meinicke, Thomas
utue.personen.roh	Broedl, Uli C.
utue.personen.roh	Woerle, Hans J.
dcterms.isPartOf.ZSTitelID	Diabetes Care	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	37	de_DE